Retrospective multiple myeloma patients showing lower mortality with HCQ treatment, unadjusted RR 0.67, p
= 0.17 (data is in the supplementary material).
Chari et al., 12/24/2020, retrospective, multiple countries, multiple regions, peer-reviewed, median age 69.0, 25 authors.
risk of death, 33.1% lower, RR 0.67, p = 0.17, treatment 8 of 29 (27.6%), control 195 of 473 (41.2%).
This study is excluded in the after exclusion results of meta analysis: unadjusted results with no group details.
Effect extraction follows pre-specified rules
prioritizing more serious outcomes. For an individual study the most serious
outcome may have a smaller number of events and lower statistical signficance,
however this provides the strongest evidence for the most serious outcomes
when combining the results of many trials.